Cross Country Healthcare, Inc. (NASDAQ:CCRN), a leading staffing agency, reported a robust fourth quarter and full year in 2023, achieving $144 million in adjusted EBITDA, despite facing headwinds in the Nurse and Allied segments. The company announced a first-quarter revenue projection of $370 million to $380 million and adjusted EBITDA estimates of $13 million to $18 million. With strategic initiatives including technology investments, offshore operations expansion, and potential mergers and acquisitions, Cross Country Healthcare is positioning itself for efficiency and growth in the upcoming year.
Key Takeaways
- Cross Country Healthcare recorded $144 million in adjusted EBITDA for the full year.
- The company launched Intellify, a vendor management system, and rebranded the Xperience app, adding data aggregation services.
- Revenue is expected to decline sequentially in the first quarter, with adjusted EBITDA projected between $13 million and $18 million.
- Long-term goals include achieving high single to low double-digit adjusted EBITDA margins.
- The company is eyeing acquisitions, particularly in the locum and education sectors, and plans to double its headcount in India, focusing on operations.
Company Outlook
- Cross Country Healthcare anticipates a rebound in healthcare staffing demand in the second half of the year.
- The company will focus on expanding its client base and diversifying services to enhance shareholder value.
- Strategic investments in technology and acquisitions are planned, along with a share repurchase program.
Bearish Highlights
- The company reported a decline in revenue and bill rates, with a focus on cost reduction measures.
- Labor disruptions in the previous quarter resulted in costs of $3-4 million.
Bullish Highlights
- Despite lower demand, the company has increased spend under management and market share.
- The Locums segment is experiencing healthy growth, with further expansion through acquisitions seen as a substantial opportunity.
Misses
- There will be fewer client renewals this year, with only 20-25% expected, compared to the last two years.
Q&A Highlights
- The company is targeting margin expansion with a high-single digit adjusted EBITDA margin goal by the end of 2024.
- The migration of MSPs to the Intellify system is nearly complete, with 80% already transitioned.
- The India operations are set to double in headcount, primarily on the operations side, to support growth and cost-saving initiatives.
- The next company update will be provided in May.
In summary, Cross Country Healthcare is navigating a challenging market with a strategic focus on technology, operational efficiency, and market expansion. The company's stable market demand and strategic execution aim to outperform competitors and achieve long-term financial goals. Despite some margin pressures and a decrease in client renewals, Cross Country Healthcare's investments and cost-saving measures, such as increasing its India operations, are expected to contribute to future growth.
InvestingPro Insights
Cross Country Healthcare, Inc. (CCRN) has been navigating through an intricate market landscape, and the latest data from InvestingPro provides a nuanced picture of the company's financial health and stock performance. Here are some key metrics and insights that investors may find valuable:
InvestingPro Data:
- The company's market capitalization stands at $598.27 million, reflecting its current market valuation.
- With a P/E ratio of 5.97, and an adjusted P/E ratio for the last twelve months as of Q3 2023 at 5.47, the stock appears to be trading at a relatively low earnings multiple compared to historical averages.
- The stock has experienced significant price volatility, with a 1-week total price return of -19.91% and a 1-month total price return of -25.29%, highlighting recent market sentiment and stock performance challenges.
InvestingPro Tips:
- Cross Country Healthcare's management has been actively engaging in share buybacks, signaling confidence in the company's value proposition and a potential upside for investors.
- The Relative Strength Index (RSI) suggests that the stock is currently in oversold territory, which could indicate a buying opportunity for contrarian investors.
In addition to these insights, there are 15 additional InvestingPro Tips available, providing a comprehensive analysis of Cross Country Healthcare's financial and stock performance. By leveraging these insights, investors can make more informed decisions. For those interested in accessing the full suite of expert tips, visit https://www.investing.com/pro/CCRN and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Full transcript - Cross Country (CCRN) Q4 2023:
Operator: Good afternoon, everyone. Welcome to Cross Country Healthcare’s Earnings Conference Call for the Fourth Quarter 2023. Please be advised that this call is being recorded and a replay of this webcast will be available on the company’s website. Details for accessing the audio replay can be found in the company’s earnings release issued this afternoon. At the conclusion of the prepared remarks, I will open the lines for questions. I would now like to turn the call over to Josh Vogel, Cross Country Healthcare’s Vice President of Investor Relations. Thank you and please go ahead, sir.
Josh Vogel: Thank you and good afternoon, everyone. I’m joined today by our President and Chief Executive Officer, John Martins; as well as Bill Burns, our Chief Financial Officer; and Marc Krug, Group President of Delivery. Today’s call will include a discussion of our financial results for the fourth quarter and full year of 2023 as well as our outlook for the first quarter of 2024. A copy of our earnings press release is available on our website at crosscountry.com. Please note that certain statements made on this call may constitute forward-looking statements. These statements reflect the company’s beliefs based upon information currently available to it. As noted in our press release, forward-looking statements can vary materially from actual results and are subject to known and unknown risks, uncertainties and other factors, including those contained in the company’s 2022 annual report on Form 10-K and quarterly reports on Form 10-Q, as well as in other filings with the SEC. The company does not intend to update guidance or any of its forward-looking statements prior to the next earnings release. Additionally, we reference non-GAAP financial measures such as adjusted EBITDA or adjusted earnings per share. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for or superior to those calculated in accordance with U.S. GAAP. More information related to these non-GAAP financial measures is contained in our press release. Also during this call, we may refer to pro forma when normalized numbers pertain to our most recent acquisitions as though the results were included or excluded from the periods presented. With that, I will now turn the call over to our Chief Executive Officer, John Martins.
John Martins: Thanks, Josh, and thank you, everyone, for joining us this afternoon. Overall, I was pleased with our fourth quarter and full year 2023 results, and particularly in how we have responded to the challenging market conditions in our Nurse and Allied segments as health systems seek ways to reduce their reliance on contingent labor. After declining in the first half of 2023, travel demand remained fairly stable. However, coming into the new year, we were seeing another pullback in orders, which appears to be industry-wide across most specialties and geographies. Many systems are nonetheless seeing increases in volumes, which we believe will ultimately translate into rising demand for our services. And with our focus on innovation and operational excellence, as well as the health of our balance sheet, Cross Country is well positioned to weather these near-term headwinds, and we believe we are poised to see sequential growth in the back half of the coming year. Now I’d like to take a moment to reflect on our full year performance. We generated $144 million of adjusted EBITDA, our second best year in company history, following the record year in 2022. We also had a record year for cash flow from operations, generating $249 million, which enabled us to end the year with a strong debt-free balance sheet. In addition, we invested more than $20 million on technology initiatives and repurchased 2.3 million shares of stock, representing approximately 6% of our outstanding shares this year. Perhaps the most noteworthy accomplishment from 2023 was the rollout of our vendor management system Intellify. This VMS technology amplifies and enhances productivity by more effectively managing, deploying, and anticipating workforce needs for our clients. Throughout the year, we witnessed the level of interest in this technology grow, leading to a series of wins that exceeded internal targets. In fact, two fairly sizable deals that we closed early in the fourth quarter were fully implemented before year-end, demonstrating the speed at which we can deploy this technology. In addition to our client-facing Intellify offering, we rebranded our Xperience app last year, which is a candidate-facing tool that enables clinicians with the power to manage their careers anytime, anyplace they want. Equally exciting, Xperience is on our roadmap to be fully integrated into Intellify. Unlike conventional job matching, Xperience ensures a precise alignment of clinicians with roles that uniquely match their skills and aspirations. In 2023, we had more than 18,000 app downloads and over 100,000 unique viewers that accessed Xperience through our mobile app and website. And finally, we launched data aggregation services, or DAS, which offers unique insights on bill rate trends that help hospitals validate their costs by providing real-time benchmarking and visibility. From an MSP and vendor-neutral sales perspective, 2023 was a very active year in our industry. And though we experienced a higher level of attrition in the earlier part of the year, we left 2023 on a very positive trajectory from both a retention and new client perspective, as well as having a robust pipeline. The annualized spend under management from our recent wins is estimated to be over $125 million when fully ramped. And since late December, we’ve had two more wins, including one verbal, with total estimated annual spend of more than $75 million. We believe that these and other wins we expect to close throughout the year will provide some tailwinds in the second half of the coming year. It’s also interesting to note that we’ve seen more balanced interest from hospital systems between MSP and vendor neutral programs, and we are strategically positioned to capitalize and grow share on both these fronts. Our focus for 2024 is on continuing to expand our client base and growing our relationships with existing clients through an expansion of services. And though we are always focused on driving efficiency, our plans for the coming year include leveraging both our offshore operations, as well as continuing to invest in cutting-edge technologies, such as AI agents and robotic process automation. These efforts will allow us to lower costs, enhance predictive job matching, improve talent sourcing, and assess candidate suitability. I look forward to sharing our progress on these and many other initiatives on future calls. Turning to the quarter, consolidated revenue was $414 million, which is above the high end of our guidance range. And though adjusted EBITDA of $21 million was within our guidance range, it would have been even higher had it not been for a charge to allowance for doubtful accounts, which Bill will cover in more detail. As expected, travel revenue in the fourth quarter was down 12% sequentially, on track with our expectations for both rates and volumes. Looking ahead, travel bill rates continue to stabilize and are trending in line with expectations. As we have called out previously, there remains a gap in expectations around bill rates with clients and pay rates from clinicians on many orders, impacting both our fill rate as well as our margins. As we navigate this dynamic, we will remain competitive in order to preserve our market share, while balancing overall profitability. Turning to our other business lines, Physician Staffing continued its strong performance with reported fourth quarter revenue of 26% year-over-year, quickly approaching an annual run rate of $200 million. Driving this was a combination of higher billable days and an improved mix of higher bill rate specialties. The segment’s contribution to income reflects the ongoing investments we are making in the business that we believe will drive organic growth and margin expansion throughout 2024. Our Education business continued to perform well, up 9% from the prior year and more than 50% from the third quarter following the start of the new school year. Our Homecare business was flat sequentially and year-over-year, though we exited the year on a solid trajectory. As we reported last quarter, we had five Homecare MSP wins and presently have nine programs in implementation. On the backs of these wins, I believe this business will experience strong organic growth in 2024. Now, turning to our outlook for the first quarter, given my earlier comments on the current market backdrop, including recent travel demand trends and industry-wide margin pressure, we anticipate that first quarter revenue will be between $370 million and $380 million, with adjusted EBITDA coming in at $13 million to $18 million. As a reminder, the annual reset in payroll taxes compresses margins at the beginning of the calendar year. I want to stress, as we work through the current market climate, we are taking actions to drive organic growth and margin expansion. In addition to ramping recent vendor-neutral and MSP wins across acute care and pay settings, we will continue to diversify physician staffing into higher margin modalities, as well as seek to capitalize on our growth and education through geographic expansion into even more markets. Additionally, we will remain diligent on the M&A front, with a goal to close on several accretive acquisitions that can further enhance our value proposition and diversify our platform into higher margin offerings. Looking ahead, we will continue to balance investments that serve to further diversify and differentiate Cross Country with necessary cost savings to preserve profitability, such as leveraging our operations in India. In fact, I just came back from India, where we held our 2024 company-wide kickoff. Coupled with the enhanced productivity and efficiency gains we are seeing through technology investments, I remain confident in our ability to drive long-term, sustainable, profitable growth, and we intend to remain focused on increasing shareholder value by leveraging our balance sheet and through the deployment of capital, including additional share repurchases, ongoing technology investments, and potential M&A opportunities. In closing, we are confident about our prospects for 2024. Outside of the broader pressures in travel, we are seeing strong momentum with Intellify, Locums, Education, and our Homecare business. The team continues to execute at a very high level, and none of this is possible without our devoted employees. We were recently named a 2023 winner of Best Company Culture and Best Company for Diversity by Comparably. These recognitions say something about our tapestry of culture that we work so hard to uphold, making Cross Country the employer destination of choice. I want to thank all of our employees and our healthcare professionals for your continued hard work and contributions, as well as our shareholders for believing in the company. With that, let me turn the call over to Bill.
Bill Burns: Thanks, John and good afternoon everyone. As John highlighted, our fourth quarter performance was largely in line with expectations, with revenue slightly exceeding the high end of our guidance range and adjusted EBITDA within our range. The outperformance on revenue was mainly attributed to better-than-expected performance across both education and physician staffing, as well as several million dollars from a labor disruption. Consolidated revenue for the fourth quarter of $414 million, was down 6% sequentially and 34% over the prior year, driven by the continued normalization in both travel demand and bill rates. I’ll get into more details on the segments in just a couple of minutes. Gross profit for the quarter was $91 million, which represented a gross margin of 21.9%. Gross margin was down 10 basis points sequentially and 20 basis points over the prior year due primarily to the tightening of the bill pay spreads for travel assignments and was partly offset by certain burdens like workers’ comp and health insurance. Moving down the income statement, selling, general and administrative expense was $68 million, down 3% sequentially and 17% over the prior year. The majority of the decrease relates to lower salary and benefit costs associated with our reductions in headcount, as well as lower variable compensation, following the historic performance throughout the pandemic. In 2023, we reduced our U.S. headcount by approximately 22% while continuing to invest in technology and areas of the business with the highest growth potential. Since the start of 2024, we have reduced our headcount by an additional 8% with plans for further reductions as we proceed throughout the coming year. As we called out, to the extent, we are unable to automate processes in the near-term, we are seeking to leverage our center of excellence in India to support our shared service teams. Over the last several quarters, we’ve grown our headcount in India by nearly 30% and we expect to double that investment in 2024. To just give you some context, for every 100 positions staffed in India, we save approximately $3 million annually. As bill pay spreads remain compressed amid softer demand, we continue to emphasize the importance of continuous productivity and efficiency gains. We are looking across the entire organization to identify opportunities to drive margins higher and to reduce our overhead, while balancing investments in capacity for future growth. Based on cost actions taken to-date, as well as lower compensation associated with a sequential decline in revenue, we anticipate total SG&A will decline in the mid single-digits for the first quarter. As a percent of revenue, SG&A was 16% in the fourth quarter, flat sequentially and up from 13% in the prior year. Our goal is to exit the year with an SG&A of 15% through a combination of organic top line growth as well as by leveraging our offshore operations, executing targeted cost savings and the further deployment of technology. For instance, the first phase of our ERP project is set to launch in Q2, and as phases are completed, we should have more opportunities to drive efficiencies. We reported adjusted EBITDA of $21 million, representing an adjusted EBITDA margin of 5%. Though revenue was above the high end of our expectations, our adjusted EBITDA was impacted by an increase in our bad debt expense. One of our MSP clients has fallen behind on payments for services rendered throughout the pandemic, leading to deterioration in the aging that requires us to take an additional reserve of $2 million for that specific account. We continue to have ongoing dialogue with the client and we’ve negotiated a payment plan that we believe will recover the remainder of the balance in the coming quarters. As revenue with the client has wound down throughout 2023, we do not anticipate a drag on top line performance in 2024. We’ll continue to monitor the situation closely and look forward to provide updates on future calls. Excluding the bad debt charge, we would have reported approximately $23 million in adjusted EBITDA, representing a 6% adjusted EBITDA margin for the quarter. Our goal remains achieving a high single to low double-digit adjusted EBITDA margin, and we continue to believe we can attain it over time. Since we’re managing this business towards long-term sustainable profitability, we must continue to make certain investments in our digital platforms as well as to ensure we have the capacity to be ready to capitalize when the travel market turns. Interest expense in the fourth quarter was $600,000, which was down 12% sequentially and 83% from the prior year. The decline was entirely driven by lower average borrowings throughout the quarter. The majority of the interest expense reported for the fourth quarter was related to the carrying costs by the ABL and fees on our outstanding letters of credit. The effective interest rate on amounts drawn under ABL was 7% as of December 31. And finally, on the income statement, income tax expense was $4 million, net of some discrete items representing an effective tax rate of 30%, essentially in line with expectations. Our overall performance resulted in adjusted earnings per share of $0.29 near the midpoint of our guidance. Turning to the segments, Nurse and Allied reported revenue of $367 million, down 7% sequentially and 38% from the prior year. Our largest business, travel nurse and allied was down 12% sequentially and 44% over the prior year. Bill rates for travel were down 4% sequentially, while billable hours were down 8%. Looking to the first quarter, we expect travel to decline sequentially in the low double-digit range, driven primarily by continued softness in travel demand, with bill rates declining in the low single-digits. After seeing travel orders rise modestly throughout the second half of last year, we’ve seen another pullback coming into the start of 2024. This seems to be an industry-wide issue across most specialties and geographies, and while orders from existing clients may rebound, we believe that our recent wins will continue to ramp, providing a catalyst to regrow our travelers on assignment. Our local or per diem business continued to feel the impact from the softness in demand as well as the timing of the holidays. Fourth quarter revenue was down 29% from the prior year, though up about 1% sequentially, due in part to the labor disruption I mentioned earlier. The majority of the year-over-year decline comes from a reduction in billable hours, as rates were down about 2% over the prior year. Also, within the Nursing Allied segment, our education business reported 9% year-over-year growth and was up 50% sequentially following the start of the new school year. Finally, Physician Staffing once again delivered a strong top line, reporting $47 million in revenue, which was up 26% over the prior year and 3% sequentially. The primary driver for the growth was a rise in the number of days filled across specialties such as anesthesiologists, CRNAs and nurse practitioners, and to a lesser extent, an increase in the average revenue per day filled. Turning to the balance sheet, we ended the year with $17 million in cash and no outstanding debt. With the help of our balance sheet and strong cash flow, we remain well-positioned to make further investments in technology and accretive acquisitions, as well as to continue repurchasing shares under our $100 million share repurchase plan. From a cash flow perspective, we generated $12 million in cash from operations in the fourth quarter, bringing the full year cash from operations to $249 million, our strongest year in company history and driven in large part by collections and reductions in net working capital. DSO was 68 days down four days since the start of the year, and excluding the impact from the single MSP client I mentioned earlier, our DSO would have been 62 days, much closer to our target. Our goal remains to bring DSO below 60 days, which is more in line with our historic performance before the pandemic and believe we can get there and make progress to that throughout the coming quarters. Cash used in investing activities was $3 million, primarily reflecting investments in our tech initiatives such as Intellify experience and our new ERP system. From a financing activity perspective, we repurchased an additional 300,000 shares during the quarter under both our 10b5-1 and our 10b-18 trading plans. This brings me to our outlook for the first quarter. We’re guiding to revenue of between $370 million and $380 million, representing a sequential decline of 8% to 11%, driven predominantly by the expected decline in both billable hours and rates for travel. We’re guiding to an adjusted EBITDA range of between $13 million and $18 million, representing an adjusted EBITDA margin of approximately 4% at the mid-point of guidance. Adjusted earnings per share is expected to be between $0.15 and $0.25 based on an average share count of 34 million shares. Also assumed in this guidance is a gross margin of between 21% and 21.5%, interest expense of $500,000, depreciation and amortization of $5 million, stock comp of $2 million, and an effective tax rate of between 32% and 33%. And that concludes our prepared remarks, and we’d now like to open the lines for questions. Operator?
Q - Kevin Fischbeck: Great. Thanks. So I guess just wanted to follow-up with some of the comments you made about how things will trend throughout the year. I guess you’re talking about sequential growth in Q2 in second half of the year, which I guess means you would think that Q2 will be down sequentially versus Q1. Is that the right way to think about it?
Bill Burns: Hey, Kevin, it’s Bill. I don’t – we’re not giving guidance to Q2 at this point, but based on how we come into the year with demand, it’s a possibility that we could see a sequential decline going into the second quarter. But it all depends on how much of that is travel, because we’re still seeing great growth across other parts of the business. So we’re not going to call out Q2 just yet as to whether it’s sequentially down or up. But as we look at the back half and as we expect our wins to ramp, our – that’s kind of our lens looking at when we think the travelers on assignment will start to regrow. John, if you want to…
John Martins: Yes. Kevin, this is John. I would just add, you’re getting a sense now that we’re getting back to that cyclical nature of this industry, back to pre-COVID, where you’re going to see traditionally a little bit of a dip in Q2 from Q1. But I do think with the recent wins that we’ve had on the MSP and VMS side, with the diversification of our businesses, as Bill mentioned, and the growth, that there’s an opportunity to buck that trend in Q2.
Kevin Fischbeck: Okay. I guess then when you say the second half is going to ramp, then are you assuming then that from an industry perspective things are going to be flattish and it’s your wins that get you to growth? Or is it a combination of the industry starting to pick up again in the back half?
John Martins: Yes, I think the way to look at it is, as we start looking at the macro data, right, and looking at, you have census and hospitals are still remaining high and increasing. Looking at the Affordable Care Act and seeing that, look we had in 2010, there was 16% of the nation didn’t have insurance and now it’s 7%, 7.2%. I think the number is, you still have this fundamental shortage of nurses, and we’re seeing that demand. We think demand will start to pick up at one point in the year. Now, I wish I had that crystal ball saying, does demand from a market standpoint start picking up sometime in the second quarter? Is it the end of the second quarter? Is it in the third quarter? It’s hard to forecast when that happens, but what we’re confident about is how we’re executing on a business, winning more deals. And so part to answer your question is part of it is, yes, we think we can outperform the market based upon the deals we’re winning, based how we’re really looking at executing above the market in many of our segments. And then add that to hopefully some market tailwinds and then we’re in a great place. But we do think that we can buck the market trend just on our wins, on our MSPs and VMS.
Bill Burns: And, Kevin, just to add a little more color to that, as you look at the macro conditions in the market, the demand today, as a snapshot, remains below the pre-pandemic, yet contingent usage by our clients is still higher. So there’s some misalignment out there right now that we do think that the demand will rebound. And I’ll just give you a little retrospective on 2023. We saw a sharp drop in the first quarter, and it kind of bounced back as we got in through the second quarter and then remained steady, probably ticking up throughout the second, third and fourth quarters. And so this is a pretty significant step down. It doesn’t seem to be something that is – that there’s a structural change in the market that would have led to that kind of a demand fall off. So it does feel a little bit perhaps of an overcorrection or a timing issue that we think can work its way back.
Kevin Fischbeck: Okay. And just to make sure I understand, how you guys talk about deals, you talked about the spend under management of 125 and then another couple of wins of 75. Are those MSPs? So we should think about those as, like, revenue numbers or is that a mix of MSP and VMS? And so it’s not necessarily a revenue way to think about it.
John Martins: Yes, it’s a mix of VMS, vendor neutral and MSPs. The vendor neutral side, we’re going to capture somewhere in that 30% range could be a little bit higher. And on the MSP side, you’re going to capture – traditionally, we capture somewhere between 65% and 70%.
Kevin Fischbeck: Okay, great. Thank you.
Operator: Thank you. Our next question comes from Brian Tanquilut with Jefferies. Your line is open.
Brian Tanquilut: Hey, good afternoon, guys. John, one of your comments, you talked about kind of keeping market share. And so just curious, how are you weighing that? Balancing market share maintenance and maybe gains versus maintaining the margins. And maybe a follow-up to that Bill, where do you think margins eventually shake out, assuming we return to kind of like a normalized level of demand?
John Martins: Brian, this is John. Yes. The market is going to do what the market’s going to do right now. And so that does put margin pressures on us as there is a – as demand softens, right, more people are going after the same jobs. So it does create some bit of a margin pressure. And so, of course, that’s how we want to balance, making sure that we’re competitive in the market, but we also want to maintain our profitability. And so that’s when we talk about the balance, and we think we’re doing a good job right now at that. And I think that’s evidenced by the wins we’ve had, and we’re not – and it’s not – we are definitely not buying the business we’re working on good margins. It’s just as an industry, the margins are moving down as a whole.
Bill Burns: Yes. Brian, I’ll add. I mentioned about how demand has stabilized, and then it kind of dropped off. The one interesting note underneath that is that when you look at the open order rates, the bill rates, they’ve remained eerily steady for quite some time. And this is looking at a subset of where we have some critical mass across ICU and Med-Surg that the majority of our demand, the large blocks. And you look and want to see what’s happened to the lock rate, the rate of the orders that you’re closing on. And what’s happening is we’re starting to see a narrowing in the spread. So in other words, we’re having to lock at lower rates, which you’re not going to necessarily be able to pay below market on the nurse compensation or the clinician’s compensation in particular, because [indiscernible] are dictated by the markets they’re going to. So you naturally will have some margin compression now. Does that foreshadow a longer tail to the margin compression? I think there’s things that the company can certainly do to mitigate that. Number one is we’re still migrating Intellify across our managed service program stack. We’re about 80% converted. I think there’s another $1 million of savings roughly to be garnered from that. And then I think we’re growing, where we are growing is in higher margin businesses, like in the home care and in our education business line. So I think we’ve got the opportunity to see consolidated margins grow. I don’t have a lens as to what happens to the pay bill spreads over time. I would hope that at some point in the future we would be able to see some bill rate improvement, but for now, that’s certainly not the market conditions we find ourselves in.
Brian Tanquilut: I appreciate it. My follow up, as I think about Locums, right, it seems like you’re seeing pretty healthy growth there. What would it take to continue driving that growth? Or maybe even expanded, like, does it have to be acquisition driven or is it contract driven or does it take more investment to grow that Locums segment?
John Martins: Well, we do love the space of Locums and of course, M&A is definitely a part of where we look at our strategy. But we’ve invested quite a bit of money over the past couple of years to build the team where it is today. So when you look at contribution income, it’s not – it’s a little lower than we want it to be right now, because that’s because we’ve made the investments. So we feel that there’s lots of – we have lots of capacity and ability to ramp this business currently and improve that bottom line margin and increase the business. But when we look at we’re approaching a $200 million company in Locums, for us to get to that next level of becoming $0.5 billion, I think that’s going to require acquisitions to get to that level.
Brian Tanquilut: Got it. Thank you.
Operator: Thank you. Next we will hear from Trevor Romeo with William Blair. You may proceed.
Trevor Romeo: Hi. Good evening. Thanks for taking the questions. First one is just kind of on client sentiment regarding contract labor. I think maybe it seems like individual hospitals might be in a variety of different spots in terms of how far they’ve reduced contract labor spend some, maybe all the way back to pre-pandemic, maybe some aren’t. I guess, if you could maybe just generalize your client base more broadly. I guess, does it feel like it’s kind of tilted one way or the other in terms of being content with current spend rates or wanting to reduce further? Or any kind of way you could summarize where your clients are at more broadly?
John Martins: Yes. Let’s take a broad – because every client is a little bit different, but let’s take a broad view. A broad view is, clients for the most part, what we’re seeing, they’re content, I say, is a good way to put it with where their labor spend is right now the number of travelers they have out there. They’re looking for ways for us to continue to help them save money. But sometimes it’s not through travel. It’s through maybe helping them with their core staff. It’s helping them with their internal resource pool, so we can maximize their internal people, which will, again, take a little bit off of the travel side. But in general, on the broad stroke, I think what we’re seeing from our clients is they’re fairly content with the number of travelers they have now. I think everyone would like to save a little bit of money a little bit more, but they also come to the realization that you could only go so far down and that if you want to make sure you have the number of beds open, if you want to make sure you have the right patient to nurse ratio, if you want to make sure that you have the nurses at the bedside taking care of the patients in the community, you need a certain level of travelers. And I think we’ve kind of hit that point. And I think that’s where when we look at saying, when do we see the bottom of this? And we’re saying, hey, again, not having that crystal ball, which I wish I had, it’s coming sometime in from now to the back half of the year and then we start seeing that sequential growth. So I think we’re almost there at that point.
Trevor Romeo: Okay. Thanks, John. That’s helpful. And then as you look into Q1, I think the sequential revenue drop you’re guiding to is quite a bit below what you typically would see Q1 over Q4. I think it’s also below what maybe some of your competitors might be expecting in Q1 in terms of the sequential change there. So I was just wondering if you could maybe try to square those differences at all and speak to maybe your level of conservatism in the guidance.
Bill Burns: Yes. Trevor, I’ll try to give you a shot. When you look at the sequential decline that’s implied in the guidance, it’s almost exclusively on the travel side, right? So we’ve talked about the fall off into demand, so we’re looking at that to say how is our net weeks books progressing? And that’s our internal metric for how we see the production. One of the things that’s interesting is even though the demand is down, we’re still booking at a fairly consistent rate overall for the start of the first quarter. I would not say there’s an error of conservativism. I think travel is the one line of business where we have a pretty good lens because of the length of the assignments. And so I think it really is not something that I’m anticipating to see a huge variance to what we’ve guided on the travel side. There is opportunity now, of course, it’s the restart of the school year as we come into the winter session or the spring session, where you can sometimes see a little bit of an uptick on the education side of the business. But I don’t know, John, if you have anything else you want to throw in there?
John Martins: What I’d say, Trevor, is that I think when you look at, you said, how we compare to our competitors, I think when you look at the growth we had over the last several years in 2021 and 2022. In 2021, staffing industry analysts is kind of how we kind of judge the market, right? And our growth, the market grew at 105% and we grew at 100%. And you got to remember we were going through our digital transformation. We were really reforming the company and really creating a new roadmap and vision for the company. And that happened in 2019 and 2020. And then in 2021 we go from nearly beating up market. And then in 2022, the market grew at 45% and Cross Country grew at 67%, clearly beating the market. And if you actually look in at the travel nurse and travel allied in particular, those numbers are actually a higher percentage of growth in 2022. And in 2023, we’re not going to be able to see what staffing industry analyst has, where the market has come down to, because they report that in sometime in the summer. And when we do see that, I’m confident that we’re going to show that we once again have outpaced the market even as the market’s going down. So I think that’s one area. And the other area, when you look to our competitors sometimes, we grew so fast in the pandemic in nurse and allied, and they may have been a little bit more diversified. So you’re going to see a little bit of difference in that. And the other thing is, I think when you look at those numbers, you have to also look at acquisitions that happen in that time period to make sure you’re comparing apples to apples.
Trevor Romeo: Okay. Thanks, John. And then maybe if I could sneak just one more in. Just wanted to follow-up on a comment I think you had in the prepared remarks about maybe having a goal to close on some acquisitions this year. Just wondering if you could kind of double click on that and maybe give us an update on what you’re seeing in terms of targets coming to market in the pipeline in your areas of interest.
John Martins: This is, I think, a buyer’s market right now. We’re seeing multiples come down. There’s companies that don’t want to go through another cycle of this downturn that we’ve seen in the market over the last 18 months. And so I think it’s a buyer’s market right now. And there’s opportunities for us. And as we’ve said before, and I said just earlier, we really love the locum [ph] space and there’s opportunities in the locum space. The allied space is something that we like. And our education business, which is just doing phenomenally as on fire. We love that space, and it’s a very fragmented space, but we’ve done a great job of growing that into a fairly sizable business. It’s nearly $100 million business. And I think there’s lots of opportunity in the education space to continue to roll up companies into that space and gain some scale in the education space.
Trevor Romeo: All right. Thank you very much.
Operator: Thank you. Our next question comes from Tobey Sommer with Truist Securities. Your line is open.
Tobey Sommer: Thanks. I know you made some comments about customer retention and market share, but I wanted to explore that a little bit more, if you could. Because it’s a little bit of a challenge externally to take the comment about gross new Intellify sales and think about a ramp to maturity and know how to use that as a modeling input. Are you trying to message that the market share you have within existing customers is stable and your income statement is just kind of transmitting trends in demand and pricing?
John Martins: Yes, that’s correct. I think I can kind of give you a little bit of flavor on where we’re at on that spend under management. When you look at our spend under management, and that includes the Intellify business. Pre-COVID, we were somewhere between $400 million to $500 million and as of December, we were at somewhere between $800 million to $900 million. And now, of course, their bill rates have gone up, but bill rates are up. Bill, what would you say, bill rates are up from that period 15%?
Bill Burns: 25%.
John Martins: 25%. Okay, so that period. So you have a 25%, 30% increase in that. But we clearly have nearly double the amount of spend under management. So we are gaining, and that’s why we think we’re gaining. We feel confident we’re gaining market share, because of those numbers. Now, look, volumes are definitely up a little bit, too, and the market size is a little bit bigger. But on the other side, demand, as Bill called out earlier on the call, demand is actually lower than pre-COVID right now. And so as we get – and that the spend of between $800 million to $900 million doesn’t account to the ramp ups of most of that $200 million plus spend under management that is still being ramped up now.
Tobey Sommer: Okay. Do you feel like the G&A is right sized and appropriate for the 1Q guidance levels? Or is it built for a different level of volume in the business?
Bill Burns: Good question, Tobey. There’s probably two pieces to that. Number one, we do have – I mentioned in my prepared remarks, we’ve had about an 8% reduction in headcount since the start of the year. We won’t get the full quarter of benefit of that. So just bearing that in mind, there is also some impact on the G&A in the first quarter from the payroll tax reset that we usually bare [ph] it’s an $0.5 million on that. And then kind of picking up some of the remarks John made. We do maintain extra capacity in the business if we were to just simply run the numbers, you’d say you could do with fewer headcount. But that’s not the place we want to be in. We don’t want to have to start from ground zero to rebuild the revenue producers that we’ve brought aboard and trained. And there’s still opportunity. The reality is, I mentioned the off-shoring of labor to India, but as important, we’re still working through a lot of different opportunities for automating a lot of our complex processes. The ERP system that we’re putting in that goes the first phase goes live, but most of the benefits of that will be really realized when we get to the second phase, which is in early 2025. So we’re not done getting at the costs in the G&A. But for Q1, that’s kind of the messaging.
Tobey Sommer: Okay, that’s helpful. Let me see. When you look at the industry, the travel nurse industry as a whole. We’re now two years in change of sort of trying to guess when the business may bottom and then finding new lows. How do you think of the industry at this point in capacity within it for the demand that exists today? And is there too much in what may need to happen to rein that capacity [ph]?
Bill Burns: Well, I guess, Tobey, I’d say that a lot of companies definitely ramped up pretty big. And I think the companies that are support from a third party perspective, the vendors that don’t have the direct client relationships are certainly going to have more capacity, I would imagine, than companies like Cross Country, where you’re still winning new direct relationships and MSP relationships.
John Martins: Yes, I think that’s fair to say, Bill. This is John. Tobey, I think that’s right where the companies that are relying on third party are definitely going to feel a bigger decline in their businesses. And as companies like Cross Country win more market share, it’s important to know like our partner networks and it’s interesting. I mentioned earlier, we have a capture rate of 65% to 70%. And why that’s important to us is we could – actually kind of goes to Trevor’s question. We could actually increase our capture rate even higher and we actually would offset maybe the decline in our revenue, but that’s not our long-term plan. One of the things that’s really important to understand about why our capture rate is between that 65% and 70% is first and foremost, when we have these clients that we’re accountable to, we want to make sure that we’re providing the highest quality clinician to the bedside to serve the patients and the communities. And unfortunately, if you want to increase that capture rate higher than something like 65% or 70%, you’d actually have to hold orders potentially, and that could affect that patient delivery. And that’s something we would never do at Cross Country. And then secondly, and I’ve called this out on calls before, is we want to make sure that we have excess capacity to win deals. And I think over the last six months, we’ve certainly proven that in the wins that we’ve had, is because we have the excess capacity, we’re able to win these deals. And then the third part of why we want to keep that capture rate in that 65% to 70% is we want to make sure we’re allowing our partner networks and these sub vendors, and these are the companies that rely on the third party business. We want them to think Cross Country as their first choice. And we want to make sure that as we’re starting to win more deals, they’re there to support our deals so that we’re keeping our clients very satisfied and happy.
Tobey Sommer: Last thing from you, if I can sneak one in. Could you talk about the market trend in MSP and VMS fees on subcontractors now that not only have you been in MSP in the marketplace for a long time, but now that you’ve got Intellify out there. Are fees to subcontractors changing at all?
John Martins: Yes, we have seen – over the years, I think from 2009, I’ve been in the industry way too long. Periodically, fees go up, and as cost pressures happen in competitive bids. What happens is we’re seeing a lot more companies go out there and offer more services and offerings to clients to win their business. And those costs have to come and be passed along to the sub vendors. So we are seeing an increase across the industry of those fees going up. But like I said, I started this industry in 2005, and every several years you see this industry grow up. I think when I first started, the average rate, I think the average fee was, I think 3% in 2004. And so over time, inflation, you have more services going to clients, they end up costing fees. And when you get, as I mentioned, when you’re getting more and more competitors and you’re seeing more and more companies trying to get into the MSP and VMS space, they’re all offering more and more, what’s the right word? Services and offerings that make it more competitive, that increase the cost of running and managing an MSP and VMS service.
Tobey Sommer: Thank you very much.
Operator: Thank you. Our next question will come from Constantine Davides with Citizens JMP. Your line is open.
Constantine Davides: Hey, Bill. Just on the labor disruption front, you called that out. I think you said a few million. Just wondering if you can put a finer point on that. And then do you have any visibility into anything disruption related that’s going to impact the first quarter?
Bill Burns: Sure, Constantine. It was between $3 million and $4 million that we got within the quarter from labor disruption, so it really wasn’t that significant. And as far as having a line of sight to Q1 labor disruptions, no, I mean, Marc is here, I don’t believe we have any demand right now. Marc, is that correct?
Marc Krug: Yes, that’s correct.
Constantine Davides: Great. And then, John, I think you mentioned 2023 tech spend of about $20 million. I just want to clarify, is that both expensed and capitalized? And I was wondering if you guys could give us some sense for what that spend is going to look like in 2024 on the technology front and where it’s being directed?
Bill Burns: Sure. Constantine, it’s Bill again. That’s correct. The number that John referenced is the combined spend across the project. So that’s capitalized and what’s been run through operating expense as well as what gets deferred. So in cloud computing it doesn’t all go on the investing activities, on your statement of cash flow, some of it is hung up in prepaids and we’ll come back in an amortization once the project is alive. But by and large, the $20-odd million is what we spent across all those projects. And for 2024, we’re anticipating spending a very similar amount.
Constantine Davides: Great. And then last one for me. Where are you guys in the migration of the MSPs over to Intellify? I remember you sort of paused that at some point last year. Just wondering if you can give us an update there? Thanks.
Bill Burns: Absolutely. Yes. I mentioned a little earlier in the Q&A that we’ve seen about 80% of our programs are now on Intellify. We’ve got a handful left that’ll go over the first or second quarter. I think we’ve got two or three in Q1 and two or three in Q2. So we’re nearly there.
John Martins: Yes. And it’s interesting on that is that a lot of times it’s not because of we don’t want to put it there. It’s really competing priorities at hospitals. And so as Bill mentioned, we would have been there earlier. It’s just matching up sometimes with the hospital and getting them set. But right now we have the roadmap to get it pretty complete pretty soon. So as Bill said, before the end of the first half, we should be at 100%.
Constantine Davides: Great. Thank you.
Operator: Thank you. [Operator Instructions] Our next question comes from Kevin Steinke with Barrington Research. You may go ahead.
Kevin Steinke: Hey, good afternoon. I believe you made a comment in your prepared remarks about margin expansion as you move through 2024. Is that correct? And if so, is that tied to just the ramp up of your Intellify business, or are you also anticipating maybe some improvement in market conditions, potentially contributing?
Bill Burns: Hey, Kevin, this is Bill. I guess I’d say we’re looking at Q1, obviously being the softest quarter. We’ve got a number of reasons for that, not realizing the full cost savings, the fact that there’s a payroll tax reset as we progress throughout the year, we’re going to continue to expect to see growth across the higher margin businesses like education. Home care in particular has a number of programs, high-single digit number of new programs that are ramping and will go live in the next few months. So there’s opportunities to see the top line grow. I think as those businesses kind of recover, we’ll see gross profit and gross margin start to rebound. I’m not making any calls right now on the bill pay spread for travel. I think we’re still in a very tough market, but that’s an opportunity. I think as we move ahead, the Intellify conversions, once we complete those that’s going to add a little over seven figures of opportunity of savings annualized for us to see that’ll contribute to our bottom line. And then finally there’s continuing to look at the opportunities for cost savings, right. So we’ve got the work that we’re moving overseas and we’ve got a very concerted effort, a very large program effort right now going across all of our teams to look and see what efforts we have that can we first automate. And John made some comments about some of the things we’re doing there in the prepared remarks. But if we’re unable to automate and it’s going to be a stable process, we’d like to look at moving that to where we can do it for the most cost effective way. So I think that’s a piece of it. And then we’re still working through all the things that will give us the opportunities to be more efficient even from our back office. We’ve had projects that we’ve been working on over the last year, many of which have been going live throughout the fourth quarter and into the first quarter. So I anticipate that we’ll still see even improvements across the shared services teams.
Kevin Steinke: Okay. And as you referenced, you think revenue could ramp sequentially in the second half of 2024. And with all those various actions and initiatives you just discussed, do you think that high-single digit adjusted EBITDA margin would be reasonable as we move towards the back half of the year?
John Martins: Yes, I think, look, that’s certainly our goal. And I made the remark in my prepared remarks that we’re targeting to exit the year with SG&A at 15% on revenue. So if you look and see where does that, where do you think gross profit or gross margin can be by the fourth quarter, you can start to back into what that could look like. But yes, something in that high single would be our goal to exit the year.
Kevin Steinke: Okay. Thanks for taking the questions.
John Martins: Sure.
Operator: Thank you. And our last question will come from Bill Sutherland with The Benchmark Company, LLC. You may proceed.
Bill Sutherland: Thank you. Hey, guys. John, I was thinking about one artifact of COVID, I think was a lot of the typical contracting cycles for MSPs got pushed out. So there’s been like a bunch up this year or last year, and maybe this year that I’ve heard is occurring in the industry. And I’m just wondering kind of what your contract cycle looks like right now as you look at your book in both MSP and VMS.
John Martins: Hey, Bill. Yes. Our cycle was heavier in 2022 and 2023, where we had more contracts up. And I think as we’ve all called out, that was because of COVID that people kind of held back and waited to go out to market after COVID, or what was perceived after COVID in 2022. So we saw a higher number of our clients go out in 2022 and 2023. This year, it’s definitely lower and less than last year. I think we’re going to see more of the typical cycle of somewhere between 20%, 25% go out this year. And it varies. Right. There’s ones that are competitive bids that, we have that our competitors are going in and getting involved in a competitive bake off, if you will. And there’s other ones that are renewals that are evergreen contracts that come up every year that were – that the client’s really not looking to go out to market. And those are the renewals that just come automatically. And of course, you still have to make sure you’re doing a great job with the client, giving the service that they need and filling there and providing the needs that they have and filling the needs they have. But there’s a couple of different categories. But to answer your question, this will be a lower year in the total number of renewals we have in the last two years.
Bill Sutherland: Got it. And I’m going to wrap up with a real quick number question Bill. Just curious, what is the headcount in India? Because you talked about increasing it this quarter I think – or first half?
Bill Burns: Yes, we haven’t, to my knowledge, given the specific India headcount out, but it’s a couple of few hundred, so it’s between 200 and 300 and ramping quickly. Now, we’ve got about today probably half of the headcount is supporting our IT operation and half of the headcount is supporting our shared services, maybe a little bit more like 60/40 operations versus IT, but we’ve been doing a lot of development work out of our India office. And so that’s part of what we’re going to continue to invest in. But the main driver of the growth is going to be on the operational side of the business. And that’s where we’re going to be more than when I say doubling the headcount; the doubling is the total headcount, but it’s going to be predominantly on the operations side. So more of the investments for the operations.
John Martins: And I think it’s important to note on that India office that we have overseas. That office has been around Cross Country for 18 years. It’s a long standing company that we’ve had there. Great partnership, great leadership there. As I mentioned in my prepared remarks, I was just there two weeks ago to do our company wide kickoff from India to all of our offices. And I can tell you the talent that we have over there is just incredible. And they’re ready to take on more and more of these services coming over. And we’re really excited about this great culture that we’ve created between the U.S. and India and truly this real partnership we have with our organization over there.
Bill Sutherland: Perfect. Thanks guys.
Operator: Thank you. Ladies and gentlemen, this does conclude the Q&A period. I’ll now turn it back over to John Martins for closing remarks.
John Martins: Thank you. In closing, I’d like to thank everyone for participating in today’s call. And we look forward to updating you on the progress of the company on our next call in May.
Operator: Ladies and gentlemen, this does conclude today’s conference call. Thank you for your participation. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.